MX2017009597A - Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100. - Google Patents

Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100.

Info

Publication number
MX2017009597A
MX2017009597A MX2017009597A MX2017009597A MX2017009597A MX 2017009597 A MX2017009597 A MX 2017009597A MX 2017009597 A MX2017009597 A MX 2017009597A MX 2017009597 A MX2017009597 A MX 2017009597A MX 2017009597 A MX2017009597 A MX 2017009597A
Authority
MX
Mexico
Prior art keywords
thiazole
dihydroimidazo
imidazo
inhibitors
derivatives useful
Prior art date
Application number
MX2017009597A
Other languages
English (en)
Inventor
East Stephen
Mackinnon Colin
Wellmar Ulf
Bainbridge Marie
Hargrave Jonathan
Carr James
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of MX2017009597A publication Critical patent/MX2017009597A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula (I) (ver Fórmula) o una sal del mismo farmacéuticamente aceptable. El compuesto es útil para usarse en el tratamiento de cáncer, un trastorno inflamatorio, un trastorno autoinmune o un trastorno neurodegenerativo.
MX2017009597A 2015-02-03 2015-12-04 Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100. MX2017009597A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153627 2015-02-03
PCT/EP2015/078683 WO2016042172A1 (en) 2015-02-03 2015-12-04 Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as s100-inhibitors

Publications (1)

Publication Number Publication Date
MX2017009597A true MX2017009597A (es) 2017-11-22

Family

ID=52446251

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009597A MX2017009597A (es) 2015-02-03 2015-12-04 Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100.

Country Status (11)

Country Link
US (1) US10385069B2 (es)
EP (1) EP3253768A1 (es)
JP (1) JP2018503692A (es)
KR (1) KR20170113627A (es)
CN (1) CN107466296A (es)
AU (1) AU2015316719A1 (es)
BR (1) BR112017016396A2 (es)
CA (1) CA2973739A1 (es)
EA (1) EA201791743A1 (es)
MX (1) MX2017009597A (es)
WO (1) WO2016042172A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11332479B2 (en) 2016-07-05 2022-05-17 Korea Institute Of Science And Technology Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same
KR101948805B1 (ko) 2016-07-05 2019-02-15 한국과학기술연구원 항종양 효과를 갖는 이미다조옥사졸 유도체 및 이를 포함하는 약학적 조성물
IL279972A (en) * 2021-01-05 2022-08-01 Anima Biotech Inc Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment
CN115448863B (zh) * 2022-10-09 2024-03-26 浙江迪邦化工有限公司 一种3,4-二氯苯基硫脲的连续化制备工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137320A (en) 1974-02-07 1979-01-30 Plantex, Ltd. Pharmaceutical compositions containing imidazo(2,1-b)thiazoles and process for reducing blood sugar levels therewith
WO2002069965A1 (en) * 2001-03-05 2002-09-12 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
GB0416396D0 (en) 2004-07-22 2004-08-25 Angeletti P Ist Richerche Bio Therapeutic agents
US7605269B2 (en) 2005-03-23 2009-10-20 Actelion Pharmaceuticals Ltd. Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists

Also Published As

Publication number Publication date
US20180282348A1 (en) 2018-10-04
CA2973739A1 (en) 2016-03-24
BR112017016396A2 (pt) 2018-03-27
CN107466296A (zh) 2017-12-12
WO2016042172A1 (en) 2016-03-24
EP3253768A1 (en) 2017-12-13
JP2018503692A (ja) 2018-02-08
US10385069B2 (en) 2019-08-20
EA201791743A1 (ru) 2017-12-29
AU2015316719A1 (en) 2017-09-07
KR20170113627A (ko) 2017-10-12

Similar Documents

Publication Publication Date Title
EP3464381A4 (en) CONNECTIONS AND METHOD FOR TREATING TROP2-POSITIVE DISEASES
PH12018500437A1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
PH12015501920A1 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
EP4010080C0 (en) HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
IL283149A (en) Inhibitors of HPK1 and their use in the treatment of cancer
PH12016500024A1 (en) Bromodomain inhibitor
FI3805233T3 (fi) N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
MX2018003215A (es) Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MY197626A (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2016015762A (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor.
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2022013274A (es) Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.
EP3250572A4 (en) Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
PH12017500159A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
MX2017009597A (es) Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
SG11202108636SA (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
EP3475442A4 (en) 12 (S) -HYDROXYEICOSATRIENOIC ACID COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS